This study is looking into whether a medication called glecaprevir/pibrentasvir (GLE/PIB) can help improve symptoms of post-traumatic stress disorder (PTSD). GLE/PIB is already approved to treat hepatitis C, and some people taking it for hepatitis C have also seen their PTSD symptoms get better. This trial wants to see if GLE/PIB works for PTSD even when someone doesn't have hepatitis C. You might be able to join if you are between 19 and 70 years old, weigh at least 45 kg, have a PTSD diagnosis, and are eligible for Veterans Affairs healthcare. The study will measure changes in your PTSD symptoms using a special scale (CAPS-5) after 8 weeks to see if the treatment is successful. The current status of this study is unclear.

Study design

This is a double-blind, randomized, placebo-controlled study with 92 participants. This means some participants will receive the active drug, and others will receive an inactive pill that looks the same, and neither you nor your doctor will know which you are receiving.

What's involved

Not specified in the trial record.

Compensation

Not stated in the trial record.

Follow-up

The primary outcome is measured at 8 weeks from the start of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.